Cargando…

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group

PURPOSE: The treatment landscape in metastatic renal cell carcinoma (mRCC) has evolved dramatically in recent years. Within the German guideline committee for RCC we evaluated current medical treatments and gave recommendations. METHODS: A systematic review of published evidence for medical treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grünwald, V., Bergmann, L., Brehmer, B., Eberhardt, B., Kastrati, Karin, Gauler, T., Gehbauer, G., Gschwend, J., Johannsen, M., Klotz, T., Protzel, C., Schenck, M., Staehler, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Topic Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512709/ https://www.ncbi.nlm.nih.gov/pubmed/35562599 http://dx.doi.org/10.1007/s00345-022-04015-1

Ejemplares similares

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
por: Wang, Y, et al.
Publicado: (2014)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?
por: Eggers, Hendrik, et al.
Publicado: (2022)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape
por: Doehn, Christian, et al.
Publicado: (2022)

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)
por: Saad, Eddy, et al.
Publicado: (2023)

SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)

28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
por: Magdy, A., et al.
Publicado: (2015)

Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy
por: Schwarzer, Adrian, et al.
Publicado: (2012)

Long-term survival in unfavourable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine
por: Karlsson-Parra, Alex, et al.
Publicado: (2015)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib
por: Ferrer, Florent, et al.
Publicado: (2021)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Reply: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Thompson Coon, J S, et al.
Publicado: (2010)

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
por: Mollica, Veronica, et al.
Publicado: (2021)

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
por: Piao, Xuan-Mei, et al.
Publicado: (2023)

Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry
por: Staehler, Michael, et al.
Publicado: (2019)

AB116. Clinical efficacy and safety of molecular targeted drugs as first-line treatment for mRCC: a systematic review and network meta-analysis
por: Mo, Chengqiang, et al.
Publicado: (2014)

Molecular subtypes and prognosis in RCC
por: Beuselinck, Benoit, et al.
Publicado: (2015)

Open Surgery for Localized RCC
por: Vander Eeckt, Kathy, et al.
Publicado: (2007)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
por: Liu, Xiaoyan, et al.
Publicado: (2019)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
por: Barata, Pedro, et al.
Publicado: (2020)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

The Multifaceted Roles of RCC1 in Tumorigenesis
por: Ren, Xuanqi, et al.
Publicado: (2020)

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
por: Liguori, Luigi, et al.
Publicado: (2023)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Isolated Scalp Nodule in Patient with Undiagnosed RCC
por: Pan, David, et al.
Publicado: (2006)

Computation of ionization-load in the traditional TPC and the RCC readout
por: Fischer, H G, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_hl5jbnalsadcgcnus8h891km3n